<DOC>
	<DOCNO>NCT00001893</DOCNO>
	<brief_summary>The propose study phase II clinical trial TNFR : Fc therapy segmental allergen bronchoprovocation model atopic asthma . The goal study ass whether inhibition tumor necrosis factor ( TNF ) bioactivity attenuate airway inflammation mild-to-moderate allergic asthmatic . This protocol utilize randomize , double-blind , placebo-controlled trial design . TNF bioactivity inhibit via systemic administration ( e.g. , subcutaneous injection ) dimeric fusion protein consist extracellular ligand bind domain 75-kilodalton TNF receptor link Fc portion human IgG1 ( TNFR : Fc , Immunex ) . The data generate study address utility anti-TNF therapy patient asthma .</brief_summary>
	<brief_title>Study TNFR : Fc ( Enbrel ) Treatment Asthma</brief_title>
	<detailed_description>The propose study phase II clinical trial TNFR : Fc therapy segmental allergen bronchoprovocation model atopic asthma . The goal study ass whether inhibition tumor necrosis factor ( TNF ) bioactivity attenuate airway inflammation mild-to-moderate allergic asthmatic . This protocol utilize randomize , double-blind , placebo-controlled trial design . TNF bioactivity inhibit via systemic administration ( e.g. , subcutaneous injection ) dimeric fusion protein consist extracellular ligand- binding domain 75-kilodalton TNF receptor link Fc portion human IgG1 ( TNFR : Fc , Immunex ) . The data generate study address utility anti-TNF therapy patient asthma .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients 18 65 year age , male female , must least 5 foot height . The diagnosis asthma require history intermittent , reversible expiratory flow limitation . Patients mildtomoderate allergic asthma define baseline force expiratory flow one second ( FEV ( 1 ) ) great 70 % predict ( least 6 hour bronchodilator use ) therapy limit inhaled betaagonists . Patients must without evidence asthma exacerbation viral upper respiratory tract infection 6 week prior entry study . Positive skin prickpuncture test one common aeroallergens . A positive inhaled methacholine challenge define decrease FEV ( 1 ) least 20 % ( PC20 ) response inhalation le 25 mg/ml methacholine . A decrease FEV ( 1 ) least 20 % response inhalation 10,000 bioequivalency allergy unit ( BAU ) allergy unit ( AU ) per ml select common aeroallergen ( house dust mite , cat hair grass ) 150 Antigen E unit per ml short ragweed . Asthmatic patient must also demonstrate late asthmatic response ( defined 20 % fall baseline establish follow completion early asthmatic response ) . Normal complete blood count , PT , PTT , serum electrolyte , mineral hepatic panel ( less 30 ml blood drawn ) , normal EKG chest radiograph without acute pulmonary infiltrates . For woman childbearing potential , negative pregnancy test 2 week prior study willingness adhere reliable birth control method study . EXCLUSION CRITERIA : Hypersensitivity TNFR : Fc Women breastfeed infant exclude risk serious adverse reaction infant TNFR : Fc unknown . Diagnosis pulmonary disorder asthma ( e.g. , chronic bronchitis , cystic fibrosis , bronchiectasis , HIVrelated lymphocytic airway inflammation ) . Respiratory tract infection asthma exacerbation within 4 week screen . Presence active infection . Use theophylline , oral inhale corticosteroid , nedocromil sodium , cromolyn sodium , zilueton , leukotriene receptor antagonist ( e.g. , zafirlukast montelukast ) , anticholinergic agent within prior 3 month . In addition , patient require ongoing therapy antihistamine , hydroxyzine , tricyclic antidepressant exclude . Research subject continue therapy inhale betaagonists study . History anaphylaxis severe allergic response . History adverse reaction lidocaine local anesthetic . Use aspirin within 2 week bronchoscopic study nonsteroidal antiinflammatory agent within 2 day bronchoscopic study . History cigarette smoking within past 3 year . History allergy immunotherapy within past year . Allergy methacholine . Positive test human immunodeficiency virus ( exclude patient HIVrelated lymphocytic airway inflammation ) . Positive test hepatitis virus ( exclude patient hepatitisrelated lung disease , pleural effusion , interstitial pneumonitis fibrosis ) . History Crohn 's disease ( exclude patient inflammatory bowel diseaserelated alveolar lymphocytosis ) . History disease associate impaired host defense , diabetes mellitus congestive heart failure . Patients impair host defense also include individual either acquire congenital , quantitative qualitative defect neutrophil , lymphocyte , monocyte/macrophage complement function . Similarly , patient require immunosuppressive therapy , chronic corticosteroid utilization 6 month cytoxic chemotherapeutic agent exclude . History chronic heart failure coronary artery disease . History central nervous system demyelinate disorder , multiple sclerosis , myelitis optic neuritis . History hematologic disorder , anemia ( iron deficiency anemia ) , thrombocytopenia leukopenia . History renal disease , chronic renal failure renal artery stenosis renal artery stent placement . History psoriasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 13, 2008</verification_date>
	<keyword>Bronchoprovocation</keyword>
	<keyword>Airway Inflammation</keyword>
	<keyword>Tumor Necrosis Factor</keyword>
	<keyword>Bronchoalveolar Lavage</keyword>
	<keyword>Pulmonary Function Test</keyword>
	<keyword>Asthma</keyword>
</DOC>